Market Research

Rheumatoid Arthritis Therapeutics Market Size, Share & Trends Analysis Report By Molecule (Pharmaceuticals, Biopharmaceuticals), By Sales Channel (Prescription, OTC), By Region, And Segment Forecasts, 2024 - 2030

Best Price Guarantee Length Publisher Published Date SKU
from $5,950 150 Pages Grand View Research July, 2024 GV19065719
Best Price Guarantee
Price from $5,950
Length 150 Pages
Publisher Grand View Research
Published Date July, 2024
SKU GV19065719

Rheumatoid Arthritis Therapeutics Market Size, Share & Trends Analysis Report By Molecule (Pharmaceuticals, Biopharmaceuticals), By Sales Channel (Prescription, OTC), By Region, And Segment Forecasts, 2024 - 2030


Rheumatoid Arthritis Therapeutics Market Growth & Trends

The global rheumatoid arthritis therapeutics market size is expected to reach USD 36.39 billion by 2030, expanding at a CAGR of 5.93% from 2024 to 2030, according to a new study by Grand View Research, Inc. expanding at a CAGR of 4.6% during the forecast period. Some of the key trends driving the market are availability of novel biologics, increase in potential clinical pipeline candidates, and rise in aging population. Thus, growing availability and awareness of safer drugs are projected to escalate rheumatoid arthritis drugs market growth.

Rheumatoid arthritis affects approximately 1% of the global population. The condition has different symptoms such as joint pain, swelling, and stiffness, which are generally accompanied by chronic pain and inability to perform daily activities. Over a prolonged period, this disorder can hamper a patient’s mobility and can lead to permanent joint damage. If left untreated, this disorder can lead to mobility impairment and risk of joint replacement.

Growing prevalence of the disease, presence of biologics & biosimilars, and well-defined regulatory guidelines are poised to provide a fillip to the market. According to the Arthritis Foundation, 64% of the population within the age group of 65 is likely to suffer from arthritis in U.S. Increasing awareness regarding disease remittance therapies and rising healthcare expenditure in developed regions are estimated to promote revenue growth.

Current treatment for rheumatoid arthritis includes generic pharmaceuticals such as NSAIDs and corticosteroids along with novel biologics such as JAK inhibitors and IL-6 antagonists, which are widely used in developed countries due to their high effectiveness. New product launches such as Infliximab and Adalimumab biosimilars are anticipated to work in favor of the market. Moreover, Eli Lilly’s Olumiant and AbbVie’s Upadacitinib are expected to cut down chances of disease remittance.

Rheumatoid Arthritis Therapeutics Market Report Highlights
  • Biopharmaceuticals segment led the market and accounted for 88.73% of the global revenue in 2023. Biopharmaceuticals are large-molecule drugs that are manufactured, extracted, and synthesized from biological sources.
  • Prescription led the market with a market share of 89.64% in 2023. As rheumatologist consultations rise, the prescription segment is expected to remain dominant in the market for rheumatoid arthritis medications over the forecast period.
  • North America rheumatoid arthritis therapeutics market accounted for 52.31% share in 2023. The regional market continues to grow and evolve, driven by demographic shifts, advancements in medical research, regulatory changes, and an increasing emphasis on personalized healthcare.
  • The Asia Pacific rheumatoid arthritis therapeutics market is experiencing significant growth, driven by the increasing prevalence of rheumatoid arthritis, improving healthcare infrastructure, and advancements in treatment options.
Please note The report will be delivered in 2-3 business days upon order notification.


Chapter 1. Methodology and Scope
1.1. Market Segmentation & Scope
1.2. Segment Definitions
1.2.1. Molecule
1.2.2. Sales channel
1.2.3. Regional scope
1.2.4. Estimates and forecasts timeline
1.3. Research Methodology
1.4. Information Procurement
1.4.1. Purchased database
1.4.2. GVR’s internal database
1.4.3. Secondary sources
1.4.4. Primary research
1.4.5. Details of primary research
1.4.5.1. Data for primary interviews in North America
1.4.5.2. Data for primary interviews in Europe
1.4.5.3. Data for primary interviews in Asia Pacific
1.4.5.4. Data for primary interviews in Latin America
1.4.5.5. Data for Primary interviews in MEA
1.5. Information or Data Analysis
1.5.1. Data analysis models
1.6. Market Formulation & Validation
1.7. Model Details
1.7.1. Commodity flow analysis (Model 1)
1.7.2. Approach 1: Commodity flow approach
1.7.3. Volume price analysis (Model 2)
1.7.4. Approach 2: Volume price analysis
1.8. List of Secondary Sources
1.9. List of Primary Sources
1.10. Objectives
Chapter 2. Executive Summary
2.1. Market Snapshot
2.2. Molecule and Sales Channel Segment Snapshot
2.3. Competitive Landscape Snapshot
Chapter 3. Rheumatoid Arthritis Therapeutics Market Variables, Trends, and Scope
3.1. Rheumatoid Arthritis Therapeutics Market Lineage Outlook
3.1.1. Parent Market Outlook
3.1.2. Ancillary market outlook - Osteoarthritis Therapeutics Market
3.2. Market Dynamics
3.2.1. Market Driver Analysis
3.2.1.1. Increasing prevalence of rheumatoid arthritis
3.2.1.2. Launch of novel therapeutic agents
3.2.1.3. Shift in treatment from the relief of symptoms to targeted therapy
3.2.1.4. Favorable reimbursement policies
3.2.2. Market Restraint Analysis
3.2.2.1. High cost of rheumatoid arthritis therapeutic drugs
3.2.2.2. Side effects and adverse reactions
3.3. Rheumatoid Arthritis Therapeutics Market Analysis Tools
3.3.1. Porter’s Five Forces Analysis
3.3.2. PESTLE Analysis
Chapter 4. Rheumatoid Arthritis Therapeutics Market Analysis, by Molecule, 2018 - 2030 (USD Million)
4.1. Rheumatoid Arthritis Therapeutics: Molecule Movement Analysis
4.2. Rheumatoid Arthritis Therapeutics Market Analysis, by Molecule Market (USD Million)
4.2.1. Biopharmaceuticals
4.2.1.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.2.1.2. Biologics
4.2.1.2.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.2.1.2.2. TNF-α antagonists
4.2.1.2.2.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.2.1.2.3. T-cell inhibitors
4.2.1.2.3.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.2.1.2.4. CD20 antigen
4.2.1.2.4.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.2.1.2.5. JAK inhibitors
4.2.1.2.5.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.2.1.2.6. anti-IL6 biologics
4.2.1.2.6.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.2.1.3. Biosimilars
4.2.1.3.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.2.1.3.2. CD20 antigen
4.2.1.3.3. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.2.1.3.4. TNF-α antagonists
4.2.1.3.5. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.2.2. Pharmaceuticals
4.2.2.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.2.2.2. NSAIDs
4.2.2.2.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.2.2.3. Analgesics
4.2.2.3.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.2.2.4. DMARDs
4.2.2.4.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.2.2.5. Glucocorticoids
4.2.2.5.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
Chapter 5. Rheumatoid Arthritis Therapeutics Market Analysis, by Sales Channel, 2018 - 2030 (USD Million)
5.1. Rheumatoid Arthritis Therapeutics: Sales Channel Movement Analysis
5.2. Rheumatoid Arthritis Therapeutics Market Analysis, by Sales Channel Market (USD Million)
5.2.1. Prescription
5.2.1.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
5.2.2. Over-the-Counter (OTC)
5.2.2.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
Chapter 6. Rheumatoid Arthritis Therapeutics Market: Regional Estimates and Trend Analysis by Molecule, by Sales Channel
6.1. Rheumatoid Arthritis Therapeutics Market: Regional Outlook
6.2. North America
6.2.1. North America Rheumatoid Arthritis Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.2.2. U.S.
6.2.2.1. Key Country Dynamics
6.2.2.2. Target Disease Prevalence
6.2.2.3. U.S. Rheumatoid Arthritis Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.2.2.4. Competitive/Market Scenario
6.2.2.5. Regulatory Framework
6.2.2.6. Reimbursement scenario
6.2.3. Canada
6.2.3.1. Key Country Dynamics
6.2.3.2. Target Disease Prevalence
6.2.3.3. Canada Rheumatoid Arthritis Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.2.3.4. Competitive/Market Scenario
6.2.3.5. Regulatory Framework
6.2.3.6. Reimbursement Scenario
6.2.4. Mexico
6.2.4.1. Key Country Dynamics
6.2.4.2. Target Disease Prevalence
6.2.4.3. Mexico Rheumatoid Arthritis Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.2.4.4. Competitive/Market Scenario
6.2.4.5. Regulatory Framework
6.2.4.6. Reimbursement Scenario
6.3. Europe
6.3.1. Europe Rheumatoid Arthritis Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.3.2. UK
6.3.2.1. Key Country Dynamics
6.3.2.2. Target Disease Prevalence
6.3.2.3. UK Rheumatoid Arthritis Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.3.2.4. Competitive/Market Scenario
6.3.2.5. Regulatory Framework
6.3.2.6. Reimbursement Scenario
6.3.3. Germany
6.3.3.1. Key Country Dynamics
6.3.3.2. Target Disease Prevalence
6.3.3.3. Germany Rheumatoid Arthritis Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.3.3.4. Competitive/Market Scenario
6.3.3.5. Regulatory Framework
6.3.3.6. Reimbursement Scenario
6.3.4. France
6.3.4.1. Key Country Dynamics
6.3.4.2. Target Disease Prevalence
6.3.4.3. France Rheumatoid Arthritis Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.3.4.4. Competitive/Market Scenario
6.3.4.5. Regulatory Framework
6.3.4.6. Reimbursement Scenario
6.3.5. Spain
6.3.5.1. Key Country Dynamics
6.3.5.2. Target Disease Prevalence
6.3.5.3. Spain Rheumatoid Arthritis Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.3.5.4. Competitive/Market Scenario
6.3.5.5. Regulatory Framework
6.3.5.6. Reimbursement Scenario
6.3.6. Italy
6.3.6.1. Key Country Dynamics
6.3.6.2. Target Disease Prevalence
6.3.6.3. Italy Rheumatoid Arthritis Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.3.6.4. Competitive/Market Scenario
6.3.6.5. Regulatory Framework
6.3.6.6. Reimbursement Scenario
6.3.7. Denmark
6.3.7.1. Key Country Dynamics
6.3.7.2. Target Disease Prevalence
6.3.7.3. Denmark Rheumatoid Arthritis Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.3.7.4. Competitive/Market Scenario
6.3.7.5. Regulatory Framework
6.3.7.6. Reimbursement Scenario
6.3.8. Sweden
6.3.8.1. Key Country Dynamics
6.3.8.2. Target Disease Prevalence
6.3.8.3. Sweden Rheumatoid Arthritis Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.3.8.4. Competitive/Market Scenario
6.3.8.5. Regulatory Framework
6.3.8.6. Reimbursement Scenario
6.3.9. 6.3.9 Norway
6.3.9.1. Key Country Dynamics
6.3.9.2. Target Disease Prevalence
6.3.9.3. Norway Rheumatoid Arthritis Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.3.9.4. Competitive/Market Scenario
6.3.9.5. Regulatory Framework
6.3.9.6. Reimbursement Scenario
6.3.9.7. Rest of Europe Rheumatoid Arthritis Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.4. Asia Pacific
6.4.1. Asia Pacific Rheumatoid Arthritis Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
6.4.2. Japan
6.4.2.1. Key Country Dynamics
6.4.2.2. Target Disease Prevalence
6.4.2.3. Japan Rheumatoid Arthritis Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.4.2.4. Competitive/Market Scenario
6.4.2.5. Regulatory Framework
6.4.2.6. Reimbursement Scenario
6.4.3. China
6.4.3.1. Key Country Dynamics
6.4.3.2. Target Disease Prevalence
6.4.3.3. China Rheumatoid Arthritis Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.4.3.4. Competitive/Market Scenario
6.4.3.5. Regulatory Framework
6.4.3.6. Reimbursement Scenario
6.4.4. India
6.4.4.1. Key Country Dynamics
6.4.4.2. Target Disease Prevalence
6.4.4.3. India Rheumatoid Arthritis Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.4.4.4. Competitive/Market Scenario
6.4.4.5. Regulatory Framework
6.4.4.6. Reimbursement Scenario
6.4.5. Australia
6.4.5.1. Key Country Dynamics
6.4.5.2. Target Disease Prevalence
6.4.5.3. Australia Rheumatoid Arthritis Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.4.5.4. Competitive/Market Scenario
6.4.5.5. Regulatory Framework
6.4.5.6. Reimbursement Scenario
6.4.6. Thailand
6.4.6.1. Key Country Dynamics
6.4.6.2. Target Disease Prevalence
6.4.6.3. Thailand Rheumatoid Arthritis Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.4.6.4. Competitive/Market Scenario
6.4.6.5. Regulatory Framework
6.4.6.6. Reimbursement Scenario
6.4.7. South Korea
6.4.7.1. Key Country Dynamics
6.4.7.2. Target Disease Prevalence
6.4.7.3. South Korea Rheumatoid Arthritis Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.4.7.4. Competitive/Market Scenario
6.4.7.5. Regulatory Framework
6.4.7.6. Reimbursement Scenario
6.4.7.7. Rest of Asia Pacific Rheumatoid Arthritis Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
6.5. Latin America
6.5.1. Latin America Rheumatoid Arthritis Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.5.2. Brazil
6.5.2.1. Key Country Dynamics
6.5.2.2. Target Disease Prevalence
6.5.2.3. Brazil Rheumatoid Arthritis Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.5.2.4. Competitive/Market Scenario
6.5.2.5. Regulatory Framework
6.5.2.6. Reimbursement Scenario
6.5.3. Argentina
6.5.3.1. Key Country Dynamics
6.5.3.2. Target Disease Prevalence
6.5.3.3. Argentina Rheumatoid Arthritis Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.5.3.4. Competitive/Market Scenario
6.5.3.5. Regulatory Framework
6.5.3.6. Reimbursement Scenario
6.5.3.7. Rest of Latin America Rheumatoid Arthritis Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.6. MEA
6.6.1. MEA Rheumatoid Arthritis Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.6.2. South Africa
6.6.2.1. Key Country Dynamics
6.6.2.2. Target Disease Prevalence
6.6.2.3. South Africa Rheumatoid Arthritis Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.6.2.4. Competitive/Market Scenario
6.6.2.5. Regulatory Framework
6.6.2.6. Reimbursement Scenario
6.6.3. Saudi Arabia
6.6.3.1. Key Country Dynamics
6.6.3.2. Target Disease Prevalence
6.6.3.3. Saudi Arabia Rheumatoid Arthritis Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.6.3.4. Competitive/Market Scenario
6.6.3.5. Regulatory Framework
6.6.3.6. Reimbursement Scenario
6.6.4. UAE
6.6.4.1. Key Country Dynamics
6.6.4.2. Target Disease Prevalence
6.6.4.3. UAE Rheumatoid Arthritis Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.6.4.4. Competitive/Market Scenario
6.6.4.5. Regulatory Framework
6.6.4.6. Reimbursement Scenario
6.6.5. Kuwait
6.6.5.1. Key Country Dynamics
6.6.5.2. Target Disease Prevalence
6.6.5.3. Kuwait Rheumatoid Arthritis Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.6.5.4. Competitive/Market Scenario
6.6.5.5. Regulatory Framework
6.6.5.6. Reimbursement Scenario
6.6.6. Rest of MEA Rheumatoid Arthritis Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
Chapter 7. Competitive Landscape
7.1. Market Participant Categorization
7.2. Key Company Profiles
7.2.1. AbbVie, Inc.
7.2.1.1. Company overview
7.2.1.2. Financial performance
7.2.1.3. Product benchmarking
7.2.1.4. Strategic initiatives
7.2.2. Boehringer Ingelheim International GmbH
7.2.2.1. Company overview
7.2.2.2. Financial performance
7.2.2.3. Product benchmarking
7.2.2.4. Strategic initiatives
7.2.3. Novartis AG
7.2.3.1. Company overview
7.2.3.2. Financial performance
7.2.3.3. Product benchmarking
7.2.3.4. Strategic initiatives
7.2.4. Regeneron Pharmaceuticals Inc.
7.2.4.1. Company overview
7.2.4.2. Financial performance
7.2.4.3. Product benchmarking
7.2.4.4. Strategic initiatives
7.2.5. Pfizer, Inc.
7.2.5.1. Company overview
7.2.5.2. Financial performance
7.2.5.3. Product benchmarking
7.2.5.4. Strategic initiatives
7.2.6. Bristol-Myers Squibb Company
7.2.6.1. Company overview
7.2.6.2. Financial performance
7.2.6.3. Product benchmarking
7.2.6.4. Strategic initiatives
7.2.7. F. Hoffmann-La Roche Ltd.
7.2.7.1. Company overview
7.2.7.2. Financial performance
7.2.7.3. Product benchmarking
7.2.7.4. Strategic initiatives
7.2.8. UCB S.A.
7.2.8.1. Company overview
7.2.8.2. Financial performance
7.2.8.3. Product benchmarking
7.2.8.4. Strategic initiatives
7.2.9. Johnson & Johnson Services, Inc.
7.2.9.1. Company overview
7.2.9.2. Financial performance
7.2.9.3. Product benchmarking
7.2.9.4. Strategic initiatives
7.2.10. AG Amgen, Inc.
7.2.10.1. Company overview
7.2.10.2. Financial performance
7.2.10.3. Product benchmarking
7.2.10.4. Strategic initiatives
7.2.11. Lilly (Eli Lilly and Company)
7.2.11.1. Company overview
7.2.11.2. Financial performance
7.2.11.3. Product benchmarking
7.2.11.4. Strategic initiatives

$5,950
$6,950
$8,950

Research Assistance

US: 800.298.5699
Int'l: +1.240.747.3093
Live help
Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Other tasks

Cookie Settings